$1.09 Earnings Per Share Expected for Pfizer Inc. (NYSE:PFE) This Quarter

Wall Street brokerages expect Pfizer Inc. (NYSE:PFE) to announce earnings per share of $1.09 for the current quarter, according to Zacks. Three analysts have made estimates for Pfizer’s earnings. The highest EPS estimate is $1.22 and the lowest is $0.96. Pfizer reported earnings per share of $0.72 during the same quarter last year, which would suggest a positive year over year growth rate of 51.4%. The business is expected to issue its next quarterly earnings results on Tuesday, October 26th.

On average, analysts expect that Pfizer will report full-year earnings of $4.08 per share for the current financial year, with EPS estimates ranging from $3.64 to $4.35. For the next year, analysts expect that the business will report earnings of $3.44 per share, with EPS estimates ranging from $2.87 to $4.24. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Pfizer.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, July 28th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. The firm had revenue of $18.98 billion for the quarter, compared to analyst estimates of $17.54 billion. Pfizer had a return on equity of 26.49% and a net margin of 23.06%. During the same quarter last year, the firm posted $0.78 EPS.

A number of research analysts have weighed in on the company. Truist assumed coverage on Pfizer in a report on Tuesday, July 27th. They issued a “buy” rating and a $43.00 price objective on the stock. Berenberg Bank restated a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a report on Tuesday, June 15th. Mizuho raised their price objective on Pfizer from $42.00 to $43.00 and gave the company a “neutral” rating in a report on Friday, July 30th. Royal Bank of Canada set a $44.00 price target on Pfizer in a report on Thursday, July 29th. Finally, SVB Leerink lifted their price target on Pfizer from $49.00 to $50.00 and gave the stock a “market perform” rating in a report on Monday. Eleven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $42.85.

PFE stock traded up $0.24 during midday trading on Thursday, reaching $44.19. The stock had a trading volume of 18,000,810 shares, compared to its average volume of 30,833,553. The company’s fifty day simple moving average is $45.38 and its 200 day simple moving average is $40.76. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. The company has a market cap of $247.76 billion, a price-to-earnings ratio of 18.97, a price-to-earnings-growth ratio of 1.58 and a beta of 0.74. Pfizer has a 52-week low of $33.36 and a 52-week high of $51.86.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 6th. Investors of record on Friday, November 5th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.53%. Pfizer’s payout ratio is 70.27%.

In other news, SVP Jennifer B. Damico sold 1,661 shares of Pfizer stock in a transaction dated Friday, August 13th. The stock was sold at an average price of $48.30, for a total value of $80,226.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jennifer B. Damico sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, July 30th. The stock was sold at an average price of $42.86, for a total value of $107,150.00. Following the sale, the senior vice president now owns 11,430 shares of the company’s stock, valued at approximately $489,889.80. The disclosure for this sale can be found here. Insiders own 0.05% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. GoalVest Advisory LLC bought a new position in Pfizer during the 2nd quarter worth approximately $39,000. Benjamin Edwards Inc. lifted its holdings in shares of Pfizer by 36.5% in the 1st quarter. Benjamin Edwards Inc. now owns 999 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 267 shares during the last quarter. Alpha DNA Investment Management LLC lifted its holdings in shares of Pfizer by 52.2% in the 1st quarter. Alpha DNA Investment Management LLC now owns 1,090 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 374 shares during the last quarter. Lake Point Wealth Management bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd lifted its holdings in shares of Pfizer by 25,460.0% in the 2nd quarter. Harvest Fund Management Co. Ltd now owns 1,278 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,273 shares during the last quarter. Institutional investors and hedge funds own 64.93% of the company’s stock.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Recommended Story: How to Invest in Stocks with Increasing Dividends

Get a free copy of the Zacks research report on Pfizer (PFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.